文献类型：期刊文献

英文题名：MAD2-p31comet axis deficiency reduces cell proliferation, migration and sensitivity of microtubule-interfering agents in glioma

作者：Wu, Dang[1];Wang, Lepeng[2];Yang, Yanhong[1];Huang, Jin[1];Hu, Yuhua[2];Shu, Yongwei[3];Zhang, Jingyu[3];Zheng, Jing[1]

机构：[1]East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, 130 Meilong Rd, Shanghai 200237, Peoples R China;[2]Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China;[3]Harbin Med Univ, Affiliated Hosp 4, Dept Neurol, Harbin 150001, Heilongjiang, Peoples R China

年份：2018

卷号：498

期号：1

起止页码：157

外文期刊名：BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000429633400024)】；

基金：This work was supported by the Shanghai Key Laboratory of New Drug Design via Shanghai Natural Science Foundation (Grant No. 15ZR1409700). We thank Dr. Shirong Wang for her help with manuscript preparation.

语种：英文

外文关键词：MAD2; p31(comet); Glioma; Cell proliferation; Microtubule-interfering agents

摘要：Mitotic arrest deficient-like-1 (MAD2, also known as MAD2L1) is thought to be an important spindle assembly checkpoint protein, which ensures accurate chromosome segregation and is closely associated with poor prognosis in many cancer. As a MAD2 binding protein, p31(comet) counteracts the function of MAD2 and leads to mitotic checkpoint silence. In this study, we explore the function of MAD2-p31(comet) axis in malignant glioma cells. Our results showed that disruption of MAD2-p31(comet) axis by comet MAD2 knockdown or p31(comet) overexpression suppressed cell proliferation, survival and migration of glioma, indicating that MAD2-p31(comet) axis is required for maintaining glioma cells malignancy. It is noted that MAD2 depletion or p31(comet) overexpression reduced the sensitivity of glioma cells to microtubule-interfering agents paclitaxel and vinblastine, providing clinical guidance for application of such drugs. Taken together, our findings suggest that MAD2-p31(comet) axis may serve as a potential therapeutic target for glioma. (C) 2018 Published by Elsevier Inc.